Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3

Status

Completed 4Unknown 1Terminated 1

Sponsor Class

OTHER 3INDUSTRY 2NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 80Breast 74Other hematologic neoplasm 25Thoracic 22Sarcoma 22Genitourinary 20Gynecologic 19Plasma cell 11CNS 11Gastrointestinal 7Tumor-Agnostic 6Classical hematology 6Head & Neck 4Endocrine 4Other solid neoplasm 3Dermatologic 2Other 1NET 1

Conditions

Neoplasms 4Neoplasm Metastasis 2Carcinoma 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × pegfilgrastim × Tumor-Agnostic × Clear all
NCT02412670 2023-07-10

Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer

Eastern Cooperative Oncology Group

Phase 2 Completed
36 enrolled 14 charts
Tumor-Agnostic

Carcinoma

NCT01214629 2018-08-06

A Study for Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
54 enrolled 23 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01214642 2018-08-06

A Dose-Escalation Study for Patients With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
63 enrolled 23 charts
Tumor-Agnostic

Neoplasms

NCT01594918 2017-07-21

Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer

University of California, San Francisco

Phase 1 Completed
25 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00751894 2011-01-19

MEG-5

University Hospital, Clermont-Ferrand

Phase 2 Unknown
30 enrolled
Tumor-Agnostic

Neoplasms

NCT00695370 2008-06-13

Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children

University Hospital, Clermont-Ferrand

Phase 2 Terminated
30 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡